Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. by Xiao, Xiao et al.
JOURNAL OF VIROLOGY, Nov. 1996, p. 8098–8108 Vol. 70, No. 11
0022-538X/96/$04.0010
Copyright q 1996, American Society for Microbiology
Efficient Long-Term Gene Transfer into Muscle Tissue of
Immunocompetent Mice by Adeno-Associated Virus Vector
XIAO XIAO,1,2 JUAN LI,1,2 AND RICHARD JUDE SAMULSKI1,3*
Gene Therapy Center1 and Department of Pharmacology,3 University of North Carolina at Chapel Hill,
Chapel Hill, North Carolina 27599, and Somatix Therapy Corporation, Alameda, California 945012
Received 11 June 1996/Accepted 31 July 1996
Muscle-directed gene transfer is being considered for the treatment of several metabolic diseases, including
hemophilia and Duchene’s muscular dystrophy. Previous efforts to target this tissue for somatic delivery with
various vector systems have resulted in transient expression due to silencing of the transgene or to an immune
response against the vector-transduced cells. We introduced recombinant adeno-associated virus vector
(rAAV) carrying a lacZ reporter into muscle tissue of immunocompetent mice. The lacZ reporter gene was
efficiently transduced and expressed with no evidence of a cellular immune response. Moreover, gene expres-
sion persisted for more than 1.5 years. Molecular characterization of rAAV vector DNA suggests a mechanism
for persistence, since vector episomes convert to high-molecular-weight genomic DNA. These data provide the
first report for establishing long-term gene transduction into mammalian muscle cells in vivo without the need
for immune modulation of the organism.
Muscle tissue has recently become an attractive target for
ex vivo and in vivo gene delivery due to the identification of
genes responsible for various diseases of this tissue and be-
cause muscle cells can be genetically modified to secrete non-
muscular therapeutic factors. Despite success with ex vivo gene
delivery via implanted myoblasts, efficient long-term gene de-
livery directly into muscle tissue has been unsuccessful (8,
36). Previously, a variety of nonviral (naked DNA [50]) and
viral (retrovirus [14] and adenovirus [41, 48]) mechanisms of
introduction have been tested. Uptake and expression can be
achieved upon injection of naked plasmids. However, gene
transfer is limited to a small percentage of the cells near the
injection site, restricting the usefulness of this method. More-
over, the plasmid DNA remains episomal and is present only
transiently, currently precluding long-term correction (32).
Viral vectors provide an alternative efficient mechanism of
delivery. Although used widely for ex vivo gene transduction,
retrovirus delivery into mature muscle tissue has been ham-
pered due to the nondividing status of these cells. Even in the
Duchene’s muscular dystrophy animal model, in which numer-
ous cells are dividing due to spontaneous regeneration, retro-
viral delivery appears inefficient when compared with DNA
transfer (11). Transgene silencing has also been observed in
this system, which has resulted in the need for further vector
modification (39). Recent reports of human immunodeficiency
virus-based vectors capable of transducing nondividing cells
may provide an alternative strategy (38). However, the safety
and efficiency of these promising vectors remain to be tested
(38). Contrary to retroviruses, recombinant adenovirus (rAd)-
based vectors are able to infect both dividing and nondividing
cells (41, 48). While transduction of nondividing cells has met
with great success, expression has been short-lived primarily
due to elimination of the rAd-transduced cells by the host
immune system (10, 51, 53, 55). Modulation of the immune
system extends transgene expression, but the episomal nature
of this vector results in eventual loss of the therapeutic gene.
Furthermore, rAd vectors seem to transduce mature muscle
cells much less efficiently than they do neonatal muscle, pos-
sibly due to limiting receptor levels (1, 2, 24, 27).
Adeno-associated virus (AAV) vectors represent a promis-
ing alternative to the above-mentioned vector systems (22, 37).
The parental wild-type AAV is nonpathogenic (6, 7). The
vector consists only of AAV inverted terminal repeats neces-
sary for replication, packaging, and integration (45). Removal
of all viral coding sequences (96% of the genome) prevents the
generation of wild-type helper virus and eliminates the possi-
bility of immune responses to residual viral gene expression (4,
19). In place of the 4.4-kb coding region, the virus can carry
and express nonviral genes of up to 5 kb (23, 37). Like the rAd
vector, rAAV can infect both dividing and nondividing cells
(20, 23, 28, 34, 37, 43). Importantly, the rAAV genome will
integrate into the host chromosome, facilitating long-term
transduction (7, 22, 37, 44). Recombinant AAV preparations
are stable and can be produced at high titers of more than 1012
particles per ml (21, 50a). An rAAV vector carrying the CFTR
gene has been tested in rabbit lung with vector transduction for
up to 6 months, providing preclinical data that has facilitated a
phase I toxicity trial in humans (13). In cultured cells, rAAV
integrates stably into host chromosomes, although recent re-
ports suggest that rAAV vectors can persist as free episomal
DNA in nondividing cells (4, 20, 43). Persistence of rAAV in
vivo has only begun to be studied in detail (4).
Here we test the ability of rAAV to transduce genes into
somatic muscle tissue of the mouse. We report the first long-
term gene transduction into this tissue, using direct virus in-
troduction. Moreover, a cellular immune response to the trans-
duced cells was not observed. Characterization of the reporter
gene which has sustained expression for more than 1.5 years
suggests that the input viral episomes are being stably main-
tained as a high-molecular-weight species, providing a viable
mechanism for establishing long-term gene transduction in
nondividing muscle cells.
MATERIALS AND METHODS
Preparation of viral vectors. Preparations of rAAV-LacZ viral vector were
made by cotransfection methods according to published protocols (34, 45) with
modifications. Briefly, at 1 to 2 h before transfection, 20 15-cm dishes of human
293 cells of 80% confluency were fed with 25 ml of fresh Iscove modified Eagle
medium (Gibco) containing 10% fetal bovine serum (Hyclone) without antibi-
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otics. Fifty micrograms of plasmid DNA (25 mg AAV-LacZ vector plasmid [25]
plus 25 mg of helper plasmid [45]) was dissolved in 2 ml of 0.25 M CaCl2 and then
quickly mixed with 2 ml of HBS buffer (50 mM HEPES, 280 mM NaCl, and 1.5
mM Na2HPO4, pH 7.12) and added to the cells. After 8 to 12 h of transfection,
the medium was replaced with fresh Dulbecco modified Eagle medium (DMEM)
(Gibco) containing 10% fetal bovine serum and antibiotics. Adenovirus type 5
(dl309) was added to the cells at a multiplicity of infection of 2. At 2.5 days
post-adenovirus infection, the cells were harvested by low-speed centrifugation,
resuspended in lysis buffer (10 mM Tris-Cl, pH 8.5, 150 mM NaCl), frozen, and
thawed four times. Cell debris was removed by low-speed centrifugation.
To the supernatant, an equal volume of ice-cold saturated (NH4)2SO4 (pH
7.0) was added and placed on ice for 20 min. The sample was then centrifuged
at 15,000 3 g for 10 min. The pellet was redissolved in CsCl-phosphate-buffered
saline (PBS) (pH 7.5) solution (density, 1.38 g/ml) and centrifuged in an SW41
rotor (Beckman) at 40,000 rpm for 48 h with a 0.5-ml CsCl-PBS cushion (density,
1.5 g/ml). The rAAV band was collected and recentrifuged as described above
for 48 h. Finally, the rAAV band was collected and dialyzed against DMEM and
heated at 568C for 15 to 30 min. The rAAV-LacZ virus titers were determined
by infecting 293 cells at various dilutions with 1 multiplicity of infection of
adenovirus type 5. The cells were fixed 24 h after infection and stained with
5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-Gal) (46). Each blue cell
was accounted as transduced by one infectious rAAV-LacZ particle.
The rAd-LacZ vector was constructed and prepared as described by Acsadi et
al. (2). The titering was performed similarly to that for rAAV-LacZ by counting
the number of blue cells transduced by rAd-LacZ.
In vivo viral delivery and detection of transgene expression. Swiss Webster
mice were purchased from Taconic (German Town, N.Y.) and handled in ac-
cordance with the institutional guidelines of the University of North Carolina.
Before virus injection, 3-week- to 4-month-old mice were anesthetized with 2.5%
Avertin intraperitoneally. Thirty microliters of rAAV-LacZ (3 3 106 infectious
units) or rAd-LacZ (3 3 106 infectious units) individually, or a 30-ml mix of
rAAV-LacZ plus rAd-LacZ (3 3 106 infectious units each) was injected into the
hind leg tibialis anterior muscles percutaneously. Secondary in vivo delivery was
carried out at different intervals by injecting the same amount of rAAV-LacZ
into the foreleg of the mice which had previously received the vector in the hind
legs.
At various time points, the mice were euthanized and the muscle tissues were
harvested and rapidly frozen in liquid nitrogen. Cryostat sectioning of the tissue
was performed at 20-mm thickness with a Leica microtone. The sections were
then fixed and stained according to previously published methods (46). The
samples were lightly stained with hematoxylin-eosin (H&E), dehydrated with
ethanol, and mounted for photography.
Southern analysis of the DNA from muscle tissues. Muscle tissues were har-
vested, minced, and suspended in lysis buffer (10 mM Tris-HCl, 100 mM EDTA,
0.5% sodium dodecyl sulfate, and 100 mg of proteinase K per ml, pH 8.0). The
samples were digested at 378C overnight and incubated for an additional 2 h after
adding 20 mg of RNase A per ml. After extraction with phenol, phenol-chloro-
form, and chloroform, the total DNA was precipitated with 0.3 M sodium acetate
and 2.5 vol of ethanol, washed twice with 70% ethanol, and redissolved in TE (10
mM Tris-Cl, 1 mM EDTA, pH 8.0). Restriction enzyme digestion with EcoRV
(New England BioLabs) was carried out overnight. DNA samples were separated
on a 1% agarose gel, and Southern hybridization was performed with Gene-
Screen Plus membrane according to the manufacturer’s standard protocol
(NEN-DuPont). The lacZ DNA probe was a 2.1-kb ClaI and NdeI fragment
labeled with [a-32P]dATP and Random Primer kit (Boehringer Mannheim).
RESULTS
Efficient transduction of muscle cells in vivo with rAAV. To
test the feasibility of gene transduction by rAAV, we inserted
a lacZ reporter gene that harbors a nuclear localization signal
under the regulation of the cytomegalovirus immediate-early
promoter into an AAV vector (25). For comparison, an ade-
novirus vector was designed to express a cytoplasmic b-galac-
tosidase (b-gal) also under CMV control. Hence, transgene
expression by the two vectors could be distinguished simulta-
neously on the basis of cellular localization of b-gal activity.
Mouse muscle tissue displays no detectable b-gal activity under
the assay conditions used (data not shown). Virus preparations
of rAAV and/or rAd were injected into the hind leg muscle of
3-week-old mice. Nine mice received rAAV-LacZ in the left
hind leg and an equal dose of rAd-LacZ in the right hind leg.
Eight additional mice received rAAV-LacZ in the left hind leg
and a mixture containing equal doses of both vectors in the
right hind leg. We then assessed (i) the transduction efficiency
of rAAV vector alone in muscle, (ii) the difference in trans-
duction efficiency between rAd and rAAV vectors in the same
animal at different injection sites, and (iii) the relative trans-
duction efficiencies when rAd and rAAV vectors were coin-
jected into the same site.
At various times post-vector delivery, mice were sacrificed
and muscle tissue was cryosectioned and stained for b-gal
activity, using X-Gal as a substrate. The experimental results
from animals 3 weeks post-vector delivery are illustrated in Fig.
1. Muscle tissue from mice injected with rAAV-LacZ vector,
either alone (left hind leg) or with rAd-LacZ (right hind leg of
same animal), showed b-gal nuclear staining within hundreds
of myotubes, indicating efficient gene transduction by the
rAAV vector (Fig. 1a, panels B, C, E, and F). In contrast, the
rAd-LacZ vector injected alone (left hind leg) or coinjected
with rAAV-LacZ (right hind leg of the same animal) trans-
duced inefficiently (less than 20 positive fibers per sections; Fig.
1a, panels A, D, B, and E). Inefficient rAd vector transduction
of mature muscle has also been observed by others (1–3, 27).
These experiments indicate that rAAV transduction, unlike
that of rAd, is efficient in mature muscle and that direct injec-
tion of viral vector is a viable approach for gene delivery.
rAAV does not elicit significant cellular immune response.
In previous experiments using adenovirus in immunocompe-
tent animals, cellular immune response was substantial, result-
ing in inflammation, tissue destruction, and eventual removal
of the transduced cells (2, 3, 9, 33, 51, 53, 55). To determine
whether similar responses were induced upon introduction of
rAAV into the muscle, we examined muscle tissue for evidence
of lymphocyte infiltration. Examination of H&E-stained tissue
samples 4 days postinjection showed marked infiltrates of all
muscles injected with rAd-LacZ (Fig. 2A). In rAd-LacZ-in-
jected samples, such infiltration was undetectable after 3 weeks
when rAd-LacZ-positive myotubes were no longer present
(Fig. 3A and B) (2, 3, 9, 33, 51, 53, 55). However, in samples
injected with rAAV vector, only mild and transient inflamma-
tion reactions were observed (Fig. 2B). Figure 2B shows some
regional infiltration reaction in rAAV-transduced tissues 4
days after injection, noticeably with many transduced cells free
of infiltration. More importantly, this inflammation was self-
limiting and disappeared at later time points without apparent
loss of transduction efficiency (Fig. 1a, panels B, C, E, and F;
Fig. 3C, D, E, and F; and Fig. 4). Interestingly, when rAAV
and rAd vectors were coinjected in the same animal at different
sites (Fig. 1a, panels C and F, and Fig. 3E and F) or identical
sites (Fig. 1a, panels B and E, and Fig. 3C and D), rAAV
nuclear b-gal expression persisted despite the strong initial
infiltration and the disappearance of rAd-transduced cells.
This result indicates that the rAAV vector does not induce a
strong cellular immune response to the transduced cell, allow-
ing for the persistence of gene expression and the preservation
of healthy tissue (3, 52, 53, 55).
Although we found no indication of a cellular (cytotoxic
T-lymphocyte [CTL]) immune response to rAAV, secondary
administration of rAAV vectors into the foreleg muscle of
mice that had been injected 9 months earlier with rAAV-LacZ
in the hind leg resulted in no additional transduction when
assayed 2 weeks after the second administration. Since control
naive adult mice were successfully transduced at later times
(Fig. 1b), initial rAAV introduction may have raised a humoral
immune response. Indeed, serum collected from rAAV-in-
jected animals inhibited rAAV transduction in cell culture. We
observed neutralizing titers of 250 to 1,250 in animals that
received a primary injection of rAAV, which after secondary
administration increased more than 25-fold to titers of greater
than 30,000 (data not shown). Since naive animals had no
neutralizing activity, these data suggest that the primary injec-
tion was sufficient to elicit a humoral response which resulted
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in significant neutralizing activity after the second administra-
tion. Nevertheless, transduced cells at the primary injection
sites in the hind leg were not affected by a second injection of
rAAV in the foreleg and no lymphocyte infiltration was found
at the primary injection site (data not shown), supporting the
conclusion that rAAV vector does not elicit a detrimental CTL
response.
Long-term gene expression in rAAV-transduced muscle
cells. Encouraged by the short-term transduction results, we
assayed the remaining mice for long-term rAAV transgene
expression at various time points from 2 months (Fig. 3C, D, E,
and F) to 19 months (Fig. 4). The rAd-LacZ expression had
diminished to undetectable levels when examined 2 months
postinjection (Fig. 3A, B, C, and D), consistent with previously
published results in immunocompetent adult animals (2, 3, 9,
33). However, rAAV-transduced animals sustained LacZ ex-
pression throughout the period tested with only limited ani-
mal-to-animal variation (Fig. 3C, D, E, and F, and Fig. 4). The
persistent transduction was not unique to animals transduced
at 3 weeks, since rAAV transduction of 4-month-old animals
FIG. 1. X-Gal staining of the cryostat sections of the tibialis anterior muscle injected with an rAd-LacZ vector and/or an rAAV-LacZ vector. (a) Three-week-old
mice were injected with rAd-LacZ (3 3 106 infectious units) (A and D), rAAV-LacZ (3 3 106 infectious units) (C and F), or rAAV-LacZ plus rAd-LacZ (3 3 106
infectious units each, in a mixture) (B and E). The arrow shows a myotube transduced by both vectors. The histochemical staining was performed at 3 weeks post-vector
injections. Panels B and C were photographed at 36.25, while panels A, D, E, and F were photographed at 325 magnifications. (b) Four-month-old mice were injected
with rAAV-LacZ (3 3 106 infectious units), and the tissues were dissected and stained at 7 days (A) and 8 months (B) post-vector injection. Magnification, 350.
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also sustained expression for at least 8 months (the period
tested) (Fig. 1b, panel B). The results of the above-mentioned
experiments are summarized in Table 1.
Molecular characterization of rAAV vector in vivo. rAAV
vectors as well as wild-type AAV have been shown to efficiently
integrate into the genomes of proliferating cells in culture (35,
37, 45). This feature of AAV provides an obvious advantage
for long-term gene transfer. Nonetheless, recent reports sug-
gest that rAAV is maintained episomally in nonproliferating
cultured cells when tested for a relatively short period of time
(1 to 14 days) (20, 43). The fact that muscle cells could be
efficiently transduced in vivo and that expression persisted for
more than 1.5 years led us to determine the molecular struc-
ture of the rAAV genomes. Total cellular DNA (both high and
low molecular weight) was isolated from muscle tissues at
various intervals 2 to 12 months post-rAAV injection. The
DNA samples were characterized by Southern analysis either
with no treatment or after digestion with EcoRV which cuts
once within the vector LacZ coding region (Fig. 5a). Using a
probe specific only for the lacZ sequences, all undigested DNA
samples from rAAV-treated tissue showed the vector DNA
migrating with high-molecular-size genomic DNA (Fig. 5b,
lanes 4, 6, 8, and 10). This high-molecular-size signal is specific,
based on its absence in control samples (Fig. 5b, lanes 12 and
FIG. 2. X-Gal and H&E staining of the cryostat sections of the tibialis anterior muscle 4 days postinjection with an rAd-LacZ vector (A) or an rAAV-LacZ vector
(B). Note the severe lymphocyte infiltration of the rAd vector-transduced myotubes (A) and milder and regional infiltration in AAV-LacZ-transduced tissue (B). The
arrows show some myotubes transduced by rAd-LacZ vector and invaded by the lymphocytes. Magnifications, 3100 (panel A) and 350 (panel B).
8102 XIAO ET AL. J. VIROL.
13). None of the untreated samples showed evidence of free
episomal forms of less than 12 kb (lanes 4, 6, 8, and 10).
Digestion with EcoRV converted the high-molecular-size vec-
tor-specific signal to a 5.0-kb unit length fragment with an
additional diffuse signal ranging from about 3 kb to more than
12 kb (lanes 5, 7, 9, and 11). Although a 5-kb fragment could
either be derived from concatemeric integration or from cir-
cular episomes (Fig. 5a), it is likely to represent a concatemeric
genomic insertion since no free low-molecular-size DNA was
detectable in the undigested samples (lanes 4, 6, 8, and 10).
FIG. 3. X-Gal staining of hind leg muscle sections 2 months post-viral vector injections into 3-week-old mice. (A and B) rAd-LacZ (3 3 106 infectious units). (C
and D) AAV-LacZ plus rAd-LacZ (33 106 infectious units each, in a mixture). (E and F) rAAV-LacZ (33 106 infectious units). Panels A, C, and E were photographed
at 36.25, while panels B, D, and F were photographed at 325 magnifications. Note that no cytoplasmic staining of rAd-LacZ-transduced cells was detected at this time
point (A, B, C, and D), while the nuclear staining from rAAV-LacZ vector persisted (C, D, E, and F).
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FIG. 4. Long-term gene expression of rAAV-LacZ vector-transduced tibialis anterior muscle tissues. Three-week-old mice were injected with rAAV-LacZ (33 106
infectious units). X-Gal staining of the cryostat sections was performed at 5 months (A and B), 8 months (C and D), 12 months (E and F), and 19 months (G and H)
post-AAV vector injections. Panels A, C, E, and G are photographed at 36.25, and panels B, D, F, and H are photographed at 350 magnifications.
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Moreover, the diffuse signal generated after EcoRV digestion,
while unusually strong, is characteristic of junction fragments
of randomly sized genomic insertion sites. Finally, the presence
of a 5.6-kb fragment in the EcoRV-digested vector-treated
samples (lanes 5, 7, 9, and 11) is indicative of a tail-to-tail
dimeric integration also seen with wild-type AAV (31). A cor-
responding head-to-head fragment would not be detected by
this assay because of the specificity of the probe. This analysis
shows no evidence of the presence of linear episomal forms
which would be indicated by the presence of 2.8- and 2.2-kb
fragments after EcoRV digestion (see lanes 5, 7, 9, and 11).
While the rAAV vector sequences appear to have stably asso-
ciated with genomic DNA, we cannot rule out a high-molecu-
lar-size, undefined episomal concatemer.
DISCUSSION
We have characterized somatic delivery into muscle tissues
of immunocompetent mice, using rAAV-LacZ vector as a
model system to examine the efficiency of vector transduction,
host immune response to transduce cells, persistence of gene
expression, and the molecular fate of the vector genome. Our
results clearly demonstrate that rAAV can transduce muscle
cells efficiently in vivo without significant cellular immune re-
sponse. In addition, we provide evidence for conversion of
monomer input rAAV genomes to high-molecular-weight spe-
cies, suggestive of integration as a mechanism for prolonged
gene transduction. These data provide the first report for es-
tablishing long-term gene transduction in mammalian muscle
cells in vivo without the need for immune modulation of the
organism.
rAAV persistence via viral integration. Recently an rAAV
vector carrying cystic fibrosis transmembrane conductance reg-
ulator (CFTR) cDNA has been reported capable of long-term
transduction in normal rabbit lungs for up to 6 months (19). In
addition, rAAV vectors have been shown to transduce neuro-
nal cells in vivo in rat brain, with prolonged expression of up to
3 months (28, 34). Moreover, rAAV vectors harboring the
human tyrosine hydroxylase gene rendered significant thera-
peutic efficacy in the Parkinsonian rat model for 4 months (28).
Although in situ PCR confirmed the presence of vector DNA
in rabbit lung (19) and rat brain (28) tissues, a detailed char-
acterization of the molecular fate of the vector sequence was
not reported. In the present study, Southern analysis supports
rAAV integration into host chromosomes as the mechanism
for persistence in mammalian muscle. Signals characteristic of
tandem head-to-tail and tail-to-tail integration were observed
after single-cut restriction endonuclease digestion similar to in
vitro integration analysis (35). Previous studies suggest that
unlike wild-type AAV, recombinants do not target integration
to a specific location (7, 44, 49). Signals characteristic of junc-
tion sequences migrating at various sizes after single-cut re-
striction endonuclease digestion support this observation. Re-
FIG. 5. Southern analysis of total DNA from rAAV-LacZ-transduced muscle
tissues collected at various time points post-vector injection. (a) Schematic dia-
gram of rAAV-LacZ vector as episome, single integrated copy (monomer), or
tandem (head-to-tail) and expected fragment sizes generated after EcoRV di-
gestion. ITR represents AAV inverted terminal repeats. Arrows are the EcoRV
cleavage sites. The wavy lines represent the genomic DNA junctions. The line
labeled “probe” is the vector fragment radiolabeled for Southern blot. (b) Au-
toradiograph of Southern blot of total DNA from vector-injected or negative
control tissues. The DNA (20 mg per lane) was untreated (lanes 4, 6, 8, 10, and
12) or digested with EcoRV (lanes 5, 7, 9, 11, and 13). Copy number standards
are PstI-digested rAAV-LacZ plasmid coloaded with 20 mg of NdeI-digested
negative control muscle DNA per lane. The 1-kb molecular size marker is
depicted on the side of the autoradiograph. The time points were 2 months
(lanes 4 and 5), 5 months (lanes 6 and 7), 11 months (lanes 8 and 9), and 1 year
(lanes 10 and 11) post-rAAV injection. The reduction of vector signal in undi-
gested lane 4 was seen multiple times and presumed to be due to masking by
high-molecular-size genomic DNA, since signal was readily detectable after
enzyme digestion (lane 5).
TABLE 1. In vivo transduction by rAd-LacZ and







Avg no. of positive fibersa
Ad-LacZ AAV-LacZ
3 wk 1 4 days 17 490
2 1 wk 580
2 3 wk 8 630
2 2 mo 0 1,250
2 4 mo 0 510
1 5 mo 760
2 8 mo 1,050
1 10 mo 700
1 12 mo 1,420
1 19 mo 450
3 mo 1 3 days 120
1 2 wk 570
4 mo 1 2 wk 430
2 8 mo 220
a The numbers of LacZ-positive fibers were determined by arbitrarily dividing
the tissue sections into four to six grid areas (four for samples with low trans-
duction and six for samples with high transduction) and counting the blue cells
or cells with blue nuclei in one or two represented areas. The total positive fiber
number in each section was then obtained by multiplying the positive cell number
in one grid or the average number from two grids by the total number of grids.
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cent analysis of rAAV in monkey airways 3 months after
administration demonstrated the presence of an episomal (pu-
tative dimer) and an uncharacterized high-molecular-weight
species in genomic DNA (4). In the present study, we did not
find evidence of a simple concatemeric (dimer) structure in-
dependent of chromosome integration. However, our analysis
could not rule out a high-molecular-weight species composed
of vector and nonvector sequences existing as a separate
minichromosome. Nor could we rule out completely the pres-
ence of both episomal and integrated copies of the vector in
these cells. In any case, our data suggest the conversion of
input vector DNA from low- to high-molecular-weight species,
with restriction digestion patterns suggestive of association
with nonvector sequences. The intensity of the vector-specific
signal after 1 year indicates an average of one to two copies per
transduced cell (Fig. 5b). Although the kinetics of rAAV inte-
gration into muscle tissue have not been addressed, by 2
months postadministration, the input vector genome had as-
sociated with high-molecular-weight DNA (Fig. 5b).
Nondividing cells are transduced by rAAV. Studies in cul-
tured cells revealed that rAAV vector can transduce resting
cells and persist either as single- or double-stranded free epi-
somal DNA (20, 40, 43). In one report, rAAV persisted as
single-stranded DNA in nondividing cells for up to 12 days
(43). When cell cycle inhibitors were removed, characteriza-
tion of the rAAV template demonstrated integration into the
chromosome (20, 40, 43). These results show that episomal
rAAV DNA in resting cells remains competent for integration
for extended periods after initial vector administration. While
indirect data such as gene expression have implied that inte-
gration in nondividing cells is possible (28, 34, 43), this issue
has remained unresolved because of technical difficulties in
analyzing episomal and integrated rAAV vectors.
In our in vivo studies, we took advantage of the natural
postmitotic nature of mature muscle cells which have an ex-
tremely slow turnover rate. In adult muscle, the majority of the
cells are mature myotubes. Histochemical staining and South-
ern analysis illustrated that the rAAV vector transduced and
persisted in these nondividing cells for more than 18 months.
This is likely the result of de novo rAAV transduction rather
than proliferation of a few transduced myoblasts. By postnatal
day 8, muscle cells are predominantly mature myotubes. Injec-
tion of vectors was carried out on postnatal day 21. In addition,
the high percentage of transduced cells (approaching 100% in
some areas) is difficult to explain by transducing a few progen-
itor cells, since massive elimination and regeneration of ma-
ture cells would be required by the earliest tested time point at
4 and 7 days postinjection (Fig. 2B and Fig. 1b, panel A). The
central nucleated morphology indicative of regenerating cells
was not observed at any significant level during our analysis
(Fig. 1 to 4). Rather, the vast majority of rAAV-LacZ-trans-
duced muscle cells possessed peripheral nucleated morphology
indicative of mature myotubes (Fig. 1 to 4).
Previous reports suggested that rAAV vectors transduce pri-
mary cells and nondividing cells less efficiently than trans-
formed and dividing cells (26, 43). Our results are in general
agreement with these observations. We have used 3 3 106
infectious units (3 3 108 viral particles) of AAV vector per
injection site in mouse muscle. If the total number of myotubes
in each injection site (around 1,000 per cross section) is con-
sidered, the transduction efficiency was about 3,000 infectious
units or 3 3 105 particles per myotube. The particle number
may be even higher at the injection site. Since myotubes are
multinucleated, a single nucleus in a fiber transduced by rAAV
vector may render the entire fiber positive after gene expres-
sion. Currently it is unclear how many of the nuclei actually
contain the vector DNA in individual myotubes. In our in vivo
experiments, the transduction efficiency was calculated to be 30
infectious units or 3,000 particles per genome. This efficiency
appears better than that of either adenovirus or plasmid DNA,
for which transducing a single myotube requires 104 to 106
adenoviruses or 1011 to 1013 DNA molecules (2, 3, 50). Al-
though rAd is excellent in transducing newborn muscles, the
same wild-type-free rAd-LacZ stock is inefficient in transduc-
ing mature muscle (2, 3, 27), suggesting an obvious reason for
the difference in efficiency we observed. As with rAd, we also
observed a decrease in transduction when using rAAV in
4-month-old compared with 3-week-old animals, although the
reduction was not as great (Fig. 1b and Table 1). These results
suggest that other variables besides vector dose may influence
optimum rAAV transduction in vivo.
Several groups have recently reported that transduction ef-
ficiency of rAAV vectors can be significantly augmented by
simultaneous treatment with genotoxic chemicals such as hy-
droxyurea or with physical agents such as UV and X-ray irra-
diation and by wild-type adenovirus or its early gene E4 ORF6
(5, 17, 18, 42). While it remains to be seen if all these methods
hold true for rAAV in vivo, preliminary data suggest that
transduction after wild-type adenovirus infection and X-ray
irradiation increases rAAV transduction (18, 50b). Although
previous work has demonstrated that wild-type adenovirus can
facilitate rAAV transduction in vitro and in vivo (17, 18), it is
unlikely that the transduction efficiency in the present experi-
ments was enhanced due to residual contaminating wild-type
adenovirus, since the rAAV vectors are gradient purified and
heat treated (see Materials and Methods). Moreover, contam-
ination of an rAd-LacZ stock with wild-type adenovirus trig-
gered a severe immune response even when delivered into
newborn rat muscle (33).
Lack of immune response supports rAAV persistence. The
fact that rAAV did not induce substantial cell-mediated im-
munogenicity is highly significant. Afione et al. and Flotte et al.
have also shown that a cellular immune response was not
mounted when using rAAV in vivo for airway-specific delivery
(4, 19). The cellular immunogenicity induced by rAd vectors is
attributed to the undesirable expression of the viral genes in
the adenovirus vectors (51–53, 55). Various efforts have been
made to either lower the extent of viral gene expression by
introducing additional viral gene mutations or to repress the
host immune system by administrating immunosuppressive
drugs (9, 15, 16, 30, 54). While most of these modifications
have improved the longevity of transduction by adenovirus
vectors and enabled secondary administration, these strategies
are still not optimum. Recent work with such modified rAd
vectors demonstrated less of an immune response to the viral
gene products, but immune response to the expressed trans-
gene persisted (47). In contrast to the adenovirus vectors, all
viral genes have been removed from rAAV, accounting for the
negligible immune response. Moreover, a cellular immune re-
sponse to the lacZ gene was not observed after rAAV trans-
duction. It is possible that the adenovirus virion itself serves as
an adjuvant owing to the complex virus structure composed of
14 distinct proteins. In contrast, the AAV virion consists pri-
marily of one major polypeptide (Vp3) (6). Our experiments
demonstrated that rAAV-LacZ vector causes only transient
and minor lymphocyte infiltration and does not elicit a CTL
response to the vector-transduced cells. Silver staining of our
vector preparations demonstrated residual foreign proteins
that may have contributed to the lymphocyte infiltration ob-
served. Since no significant CTL response was induced in the
experiments reported here using rAAV, this also supports the
absence of wild-type adenovirus contamination. The transient
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inflammatory reaction observed in rAAV-injected sites could
have been induced by physical damage to the muscle tissue
during the injection or due to impurities in the virus prepara-
tion. Indeed, when similar rAAV-LacZ stocks were delivered
through the coronary artery to the heart muscle, a noninvasive
means to the muscle tissue, efficient and long-term transduc-
tion was achieved without any sign of lymphocyte infiltration
(29). In addition, direct injection of a retroviral vector devoid
of any viral genes also induced inflammatory reactions in the
muscle tissue (11). Regardless of the transient immune re-
sponse we observed, when rAAV-LacZ and rAd-LacZ were
coinjected into the same sites, rAAV-transduced cells pre-
vailed while rAd-transduced cells were diminished. Further-
more, upon secondary delivery of rAAV vector, the numerous
myotubes transduced by rAAV at the primary sites were un-
affected even though a significant neutralizing response could
be detected (data not shown).
Even if immune problems associated with rAd vectors are
eventually overcome, the fact that transduced genomes remain
episomal suggests that repeated dosing will be inevitable. Al-
though repeated administration of rAAV-LacZ was unsuccess-
ful due to a humoral response, repeated dosing appears not to
be necessary given that the originally transduced cells escaped
a CTL response and persisted long term. Since greater than
80% of the public is seropositive for AAV, it raises the ques-
tion of viable vector delivery in general. However, the percent-
age of seropositive individuals that are also positive for neu-
tralizing antibody remains to be determined. Moreover,
already-established strategies for manipulating the host im-
mune system for rAd-repeated dosing (9, 13, 30, 54) could also
be modified and adopted for the rAAV vector system. In the
case of rAAV, transient suppression of the humoral responses
should be sufficient. Recent success with different serotypes of
rAAV should also be valuable if repeated dosing is necessary
(33a).
In summary, we have demonstrated that rAAV can be used
as an efficient, safe, and practical in vivo gene therapy vector.
By means of direct injection, rAAV vectors transduced muscle
tissue of immunocompetent mice without significant detrimen-
tal immune consequences, resulting in sustained long-term ex-
pression. Stable persistence of the vector genome with the host
indicates that rAAV vector-mediated gene therapy may be of
general use for numerous metabolic disorders.
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